{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T11:08:30Z","timestamp":1773745710432,"version":"3.50.1"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>Non-functioning pituitary adenomas (NFPAs) exhibit high recurrence rates after surgery. However, the determinants of recurrence are inconsistent in the available literature. The present study sought to investigate the association between nuclear phosphorylated EGFR (pEGFR) levels and recurrence of NFPAs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Tissue microarrays from patients undergoing adenomectomy for NFPAs at our tertiary care center from 2003 to 2015 and having a minimum of 60 months of follow-up (n=102) were accessed. Immunohistochemical analysis (IHC) was performed to determine the expression of nuclear pEGFR T693. h-score was calculated as the product of staining intensity and the number of positively staining cells. Radiological surveillance (MRI) was performed to categorize NFPAs as recurrent or non-recurrent on follow-up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The mean age of the cohort was 50 \u00b1 11 years with a male preponderance (61.1%). Recurrence was observed in 46.1% of the patients at a median of 123 months (IQR 72-159) of follow-up. pEGFR T693 positivity was higher in a significantly greater number of recurrent NFPAs as compared to non-recurrent NFPAs (95.7%<jats:italic>vs<\/jats:italic>81%, p=0.02). h-scores were also significantly higher in recurrent NFPAs (122.1 \u00b1 6<jats:italic>vs<\/jats:italic>81.54 \u00b1 3.3, p&amp;lt;0.0001). pEGFR T693 positivity significantly predicted recurrence in NFPAs (HR=4.9, CI 2.8-8.8, p&amp;lt;0.0001). ROC analysis revealed an h-score cutoff of 89.8 as being associated significantly with recurrence (sensitivity 80%, specificity 78%, AUC 0.84, p&amp;lt;0.0001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>pEGFR T693 was expressed in significantly higher number of recurrent NFPAs. The h-scores were also higher in recurrent NFPAs. Nuclear pEGFR T693 may serve as a predictor of recurrence in NFPAs.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2021.708111","type":"journal-article","created":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T13:09:26Z","timestamp":1625490566000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Phosphorylated EGFR (pEGFR T693) as a Novel Predictor of Recurrence in Non-Functioning Pituitary Adenomas"],"prefix":"10.3389","volume":"12","author":[{"given":"Ashutosh","family":"Rai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liza","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanchan K.","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sivashanmugam","family":"Dhandapani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manjul","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chirag Kamal","family":"Ahuja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bishan Dass","family":"Radotra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pinaki","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1159\/000339823","article-title":"Natural History of Postoperative Nonfunctioning Pituitary Adenomas: A Systematic Review and Meta-Analysis","volume":"96","author":"Chen","year":"2012","journal-title":"Neuroendocrinology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1227\/NEU.0000000000001386","article-title":"Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Management of Patients With Nonfunctioning Pituitary Adenomas: Executive Summary","volume":"79","author":"Aghi","year":"2016","journal-title":"Neurosurgery"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ando.2015.04.002","article-title":"Management of Clinically Non-Functioning Pituitary Adenoma","volume":"76","author":"Chanson","year":"2015","journal-title":"Ann Endocrinol [Paris]"},{"key":"B4","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1530\/EJE-10-0255","article-title":"Factors Predicting Relapse of Nonfunctioning Pituitary Macroadenomas After Neurosurgery: A Study of 142 Patients","volume":"163","author":"Brochier","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3390\/cancers9050052","article-title":"Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways","volume":"9","author":"Wee","year":"2017","journal-title":"Cancers (Basel)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.22.2.237","article-title":"EGFR Family Signaling and Its Association With Breast Cancer Development and Resistance to Chemotherapy","volume":"22","author":"Navolanic","year":"2003","journal-title":"J Int J Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12587","article-title":"The Prevalence of EGFR Mutation in Patients With Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.05.007","article-title":"Nuclear Interaction of EGFR and STAT3 in the Activation of the iNOS\/NO Pathway","volume":"7","author":"Lo","year":"2005","journal-title":"Cancer Cell"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.20876","article-title":"Nuclear-Cytoplasmic Transport of EGFR Involves Receptor Endocytosis, Importin Beta1, and CRM1","volume":"98","author":"Lo","year":"2006","journal-title":"J Cell Biochem"},{"key":"B10","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/modpathol.2009.166","article-title":"Nuclear EGFR in Ductal Invasive Breast Cancer: Correlation With Cyclin-D1 and Prognosis","volume":"23","author":"Hadzisejdi\u0107","year":"2010","journal-title":"Mod Pathol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2013.03.020","article-title":"Nuclear EGFR Protein Expression Predicts Poor Survival in Early Stage Non-Small Cell Lung Cancer","volume":"81","author":"Traynor","year":"2013","journal-title":"Lung Cancer"},{"key":"B12","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.338.65.1","article-title":"Novel Prognostic Value of Nuclear Epidermal Growth Factor Receptor in Breast Cancer","volume":"65","author":"Lo","year":"2005","journal-title":"Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/mc.20504","article-title":"Nuclear Expression of Epidermal Growth Factor Receptor Is a Novel Prognostic Value in Patients With Ovarian Cancer","volume":"48","author":"Xia","year":"2009","journal-title":"Mol Carcinog"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2013.06.010","article-title":"Nuclear EGFR as a Molecular Target in Cancer","volume":"108","author":"Brand","year":"2013","journal-title":"Radiother Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/ncb0901-802","article-title":"Nuclear Localization of EGF Receptor and Its Potential New Role as a Transcription Factor","volume":"3","author":"Lin","year":"2001","journal-title":"Nat Cell Biol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1501","article-title":"Tyrosine Phosphorylation Controls PCNA Function Through Protein Stability","volume":"8","author":"Wang","year":"2006","journal-title":"Nat Cell Biol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.9756","article-title":"Higher Nuclear EGFR Expression Is a Better Predictor of Survival in Rectal Cancer Patients Following Neoadjuvant Chemoradiotherapy Than Cytoplasmic EGFR Expression","volume":"17","author":"Yang","year":"2019","journal-title":"Oncol Letters."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2003.11.041","article-title":"Review of Epidermal Growth Factor Receptor Biology","volume":"59","author":"Herbst","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/300192a0","article-title":"Epidermal Growth Factor Rapidly Stimulates Prolactin Gene Transcription","volume":"300","author":"Murdoch","year":"1982","journal-title":"Nature"},{"key":"B20","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1210\/me.2010-0353","article-title":"HER2\/ErbB2 Receptor Signaling in Rat and Human Prolactinoma Cells: Strategy for Targeted Prolactinoma Therapy","volume":"25","author":"Fukuoka","year":"2011","journal-title":"Mol Endocrinol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800118","article-title":"Analysis of Epidermal Growth Factor Receptor and Activated Epidermal Growth Factor Receptor Expression in Pituitary Adenomas and Carcinomas","volume":"17","author":"Onguru","year":"2004","journal-title":"Modern Pathol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1210\/jc.81.2.656","article-title":"Epidermal Growth Factor and Its Receptor (EGF-R) in Human Pituitary Adenomas: EGFR Correlates With Tumor Aggressiveness","volume":"81","author":"LeRiche","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1580425","article-title":"Epidermal Growth Factor Binding Sites in Human Pituitary Macroadenomas","volume":"158","author":"Jaffrain-Rea","year":"1998","journal-title":"J Endocrinol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.dib.2018.03.085","article-title":"Data of Phosphoproteomic Analysis of Non-Functioning Pituitary Adenoma","volume":"18","author":"Rai","year":"2018","journal-title":"Data Brief."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-015-0802-8","article-title":"Locally Produced Estrogen Through Aromatization Might Enhance Tissue Expression of Pituitary Tumor Transforming Gene and Fibroblast Growth Factor 2 in Growth Hormone-Secreting Adenomas","volume":"52","author":"Ozkaya","year":"2016","journal-title":"Endocrine"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-013-1084-y","article-title":"A New Prognostic Clinicopathological Classification of Pituitary Adenomas: A Multicentric Case\u2013Control Study of 410 Patients With 8 Years Post-Operative Follow-Up","volume":"126","author":"Trouillas","year":"2013","journal-title":"Acta Neuropathologica"},{"key":"B27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11102-011-0347-7","article-title":"Clinical Factors Involved in the Recurrence of Pituitary Adenomas After Surgical Remission: A Structured Review and Meta-Analysis","volume":"15","author":"Roelfsema","year":"2012","journal-title":"Pituitary"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-4061","article-title":"Outcome of Nonfunctioning Pituitary Adenomas That Regrow After Primary Treatment: A Study From Two Large UK Centers","volume":"102","author":"Tampourlou","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-20-0136","article-title":"The Natural History and Treatment of Non-Functioning Pituitary Adenomas (Non-Functioning PitNETs)","volume":"27","author":"Yavropoulou","year":"2020","journal-title":"Endocr Rel Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-017-0857-z","article-title":"Malignant Transformation in non-Functioning Pituitary Adenomas (Pituitary Carcinoma)","volume":"21","author":"Lenders","year":"2018","journal-title":"Pituitary"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2003.01784.x","article-title":"Postoperative Surveillance of Clinically Nonfunctioning Pituitary Macroadenomas: Markers of Tumor Quiescence and Regrowth","volume":"58","author":"Greenman","year":"2003","journal-title":"Clin Endocrinol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14791\/btrt.2016.4.1.1","article-title":"Clinical Concerns About Recurrence of Non-Functioning Pituitary Adenoma","volume":"4","author":"Lee","year":"2016","journal-title":"Brain Tumor Res Treat"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-17-0965","article-title":"Both Invasiveness and Proliferation Criteria Predict Recurrence of Non-Functioning Pituitary Macroadenomas After Surgery: A Retrospective Analysis of a Monocentric Cohort of 120 Patients","volume":"178","author":"Lelotte","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-18-0291","article-title":"MRI Texture Analysis as a Predictor of Tumor Recurrence or Progression in Patients With Clinically Non-Functioning Pituitary Adenomas","volume":"179","author":"Galm","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-017-1447-6","article-title":"Clinical Profile of Silent Growth Hormone Pituitary Adenomas; Higher Recurrence Rate Compared to Silent Gonadotroph Pituitary Tumors, A Large Single Center Experience","volume":"58","author":"Langlois","year":"2017","journal-title":"Endocrine"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2009.03673.x","article-title":"Silent Corticotroph Adenomas Have Unique Recurrence Characteristics Compared With Other Nonfunctioning Pituitary Adenomas","volume":"72","author":"Cho","year":"2010","journal-title":"Clin Endocrinol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01956","article-title":"Recurrence of Silent Corticotroph Adenomas After Primary Treatment: A Systematic Review and Meta-Analysis","volume":"104","author":"Fountas","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e16148","DOI":"10.1097\/MD.0000000000016148","article-title":"Differential Circular RNA Expression Profiles of Invasive and Non-Invasive Non-Functioning Pituitary Adenomas: A Microarray Analysis","volume":"98","author":"Hu","year":"2019","journal-title":"Medicine"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3892\/or.2018.6851","article-title":"A Two\u2212circRNA Signature Predicts Tumor Recurrence in Clinical Non\u2212Functioning Pituitary Adenoma","volume":"41","author":"Guo","year":"2019","journal-title":"Oncol Rep"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2017.6169","article-title":"Increased \u03b2\u2212Catenin and C-Myc Expression Predict Aggressive Growth of Non-Functioning Pituitary Adenomas: An Assessment Using a Tissue Microarray-Based Approach","volume":"15","author":"Liu","year":"2017","journal-title":"Mol Med Rep"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-018-0890-4","article-title":"Phosphoproteome Profiling Revealed Abnormally Phosphorylated AMPK and ATF2 Involved in Glucose Metabolism and Tumorigenesis of GH-PAs","volume":"42","author":"Zhao","year":"2019","journal-title":"J Endocrinol Invest"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s13167-020-00215-0","article-title":"Integration of Quantitative Phosphoproteomics and Transcriptomics Revealed Phosphorylation-Mediated Molecular Events as Useful Tools for a Potential Patient Stratification and Personalized Treatment of Human Nonfunctional Pituitary Adenomas","volume":"11","author":"Liu","year":"2020","journal-title":"EPMA J"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1126\/science.274.5295.2086","article-title":"Control of EGF Receptor Signaling by Clathrin-Mediated Endocytosis","volume":"274","author":"Vieira","year":"1996","journal-title":"Science"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2017.11.034","article-title":"ADAM12 Induces EMT and Promotes Cell Migration, Invasion and Proliferation in Pituitary Adenomas via EGFR\/ERK Signaling Pathway","volume":"97","author":"Wang","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fendo.2019.00785","article-title":"Expression of EGFR in Pituitary Corticotroph Adenomas and Its Relationship With Tumor Behavior","volume":"10","author":"Liu","year":"2019","journal-title":"Front Endocrinol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602941","article-title":"Nuclear EGFR Signalling Network in Cancers: Linking EGFR Pathway to Cell Cycle Progression, Nitric Oxide Pathway and Patient Survival","volume":"9","author":"Lo","year":"2006","journal-title":"Br J Cancer"},{"key":"B47","article-title":"The Nuclear Epidermal Growth Factor Receptor Signaling Network and its Role in Cancer","volume":"12","author":"Brand","year":"2011","journal-title":"Discov Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.143r001","article-title":"Cyclin D and Cyclin E Expression in Normal and Adenomatous Pituitary","volume":"143","author":"Jordan","year":"2000","journal-title":"Eur J Endocrinol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30155-4","article-title":"Advances in the Medical Treatment of Cushing\u2019s Syndrome","volume":"7","author":"Feelders","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa805","article-title":"EGFR\/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas","volume":"106","author":"Cooper","year":"2021","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.708111\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T21:40:37Z","timestamp":1672695637000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.708111\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,5]]},"references-count":50,"alternative-id":["10.3389\/fendo.2021.708111"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.708111","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,5]]},"article-number":"708111"}}